Latest From Biotech Now

Confused Consumers are a Desirable Bonus of I-522

No-on-522-2 copy

With less than a month out, Washington State Initiative 522 continues to garner more and more attention of state voters. If enacted, the law would require labeling of genetically engineered foods on the packaging of raw agricultural commodities, processed foods, and seed and seed stock, or on retail shelf signage for unpackaged products. Exemptions to these regulations would be provided under the measure.  If found in violation of not meeting the labeling requirements, offenders could Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

The New Road to IPO in the Age of the JOBS Act

President Obama

Not surprisingly, sessions discussing the topic of IPOs at this year’s BIO Investor Forum, tend to fill the room. Furthermore, it should surprise no one that this year’s IPO discussions were upbeat. That is mostly attributable to the dramatically higher number of IPOs that have already occurred this year. Furthermore, according to Jeff Baumel, moderator of a panel covering this very topic, deals are closing faster this year – with a median time of just Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

BIO Patient and Health Advocacy Summit: Patient-Focused Drug Development

95468934

Panelists in this morning’s opening session outlined strategies for the FDA to better engage the patient community to guide the drug development process. “Patients should be providing input and guidance throughout the entire drug review process,” said Marc Boutin, Executive VP and COO of the National Health Council. Boutin highlighted the improvements made through PDUFA V to open up and enhance the Agency’s interaction and engagement with patients. “Integrating our perspective into how drugs are Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

The “Designer Baby” Patent: Why the Patent System Should Not Regulate Science

family_115x76

23andMe received criticism this week from a few bioethicists in the journal Genetics in Medicine, regarding a patent titled “gamete donor selection based on genetic calculations.”   The ethicists write,  “Selecting children in ways such as those patented by 23andMe is hugely ethically controversial… We believe the patent office made a serious mistake in allowing a patent that includes drop-down menus from which to choose a future child’s traits… At no stage during the examination of the patent application Read More >

Patently BIOtech  |  2 Comments  |  Email This Post
Tags: , ,

Biotech IPO Boom or Bubble? The Opening Plenary at the BIO Investor Forum

David Thomas

With 31 (and counting) life sciences companies having already placed IPOs on the market within the first 8 months of this year and many others lining up for S-1 filings, biotech is buzzing about a revival of the IPO market. Is it a bubble? David Thomas, director of Industry Research and Analysis at BIO took up these questions during the opening plenary lunch of the 12th Annual BIO Investor Forum. What’s his short answer? Not Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,